Medication-related osteonecrosis
MRONJ risk depends on the medicine, its indication and the patient’s wider circumstances. The aim is to prevent avoidable disease while still providing necessary dental care. Distinguish risk assessment from a diagnosis of established necrosis, and distinguish MRONJ from osteoradionecrosis and malignant bone disease.
Quick revision summary
Understand the medicines and disease mechanism
Antiresorptive medicines reduce bone resorption and include bisphosphonates and denosumab. Regimens used in cancer and osteoporosis differ substantially, so route alone is an incomplete risk classification. Antiangiogenic and other medicines can also be relevant; consult the current SDCEP resources and supplement for the actual agent.
Plan extraction and alternatives proportionately
Consider whether a restorable tooth can be maintained with endodontic or restorative care, balancing infection control and prognosis. A hopeless infected tooth should not simply be retained indefinitely to avoid surgery.
Manage symptoms, extent and future risk
Specialist treatment may include local hygiene measures, pain relief, treatment of infection when indicated and surgery selected for symptoms, stage, anatomy and patient goals. Conservative care and operative care are options within a considered plan; neither is universally correct for every lesion.
Common mistake
Never create a drug holiday independently. Avoiding every extraction is not prevention when a persistent infected tooth itself requires treatment.
Medication-related osteonecrosis: prevention, diagnosis and care
MRONJ risk depends on the medicine, its indication and the patient’s wider circumstances. The aim is to prevent avoidable disease while still providing necessary dental care. Distinguish risk assessment from a diagnosis of established necrosis, and distinguish MRONJ from osteoradionecrosis and malignant bone disease.
Understand the medicines and disease mechanism
Antiresorptive medicines reduce bone resorption and include bisphosphonates and denosumab. Regimens used in cancer and osteoporosis differ substantially, so route alone is an incomplete risk classification. Antiangiogenic and other medicines can also be relevant; consult the current SDCEP resources and supplement for the actual agent.
MRONJ has a multifactorial biology involving altered remodelling, local infection or inflammation and tissue factors. Extraction can precede it, but periodontal or periapical disease and spontaneous presentations also matter. Avoid the simplistic claim that a clean surgical technique eliminates risk or that every non-healing socket in an exposed patient is automatically MRONJ.
Take a precise medicine and dental history
Record drug name, indication, route, frequency, duration and whether treatment is ongoing or previous. Include corticosteroids, chemotherapy and other relevant therapies, previous MRONJ and any head and neck radiotherapy. Bisphosphonates remain in bone; a remote stop date does not necessarily remove the risk.
Ask about dental pain, exposed bone, discharge, altered sensation and previous healing. Assess caries, periodontal disease, dentures and mucosal trauma. The SDCEP risk framework supports routine dental planning, but risk communication should be individualised and acknowledge uncertainty, particularly with combinations and less well-characterised medicines.
Prioritise prevention and coordination
Where feasible, assess oral health before relevant treatment begins, addressing active disease and teeth with a poor prognosis in coordination with the prescribing team. Do not independently delay essential cancer or skeletal therapy. Good prevention reduces the likelihood of future infection and invasive intervention.
Ongoing care includes fluoride-based prevention, periodontal control, maintainable restorations and denture review. Explain warning symptoms without discouraging routine dental attendance. Necessary dentistry should not be refused solely because a patient takes an antiresorptive drug; use the risk assessment and an appropriate care setting.
Plan extraction and alternatives proportionately
Consider whether a restorable tooth can be maintained with endodontic or restorative care, balancing infection control and prognosis. A hopeless infected tooth should not simply be retained indefinitely to avoid surgery. Discuss MRONJ alongside risks of untreated disease and reasonable alternatives.
Use current SDCEP advice for the risk group, consent, treatment and review. Do not prescribe prophylactic antibiotics or antiseptics solely as a universal MRONJ prevention measure without a guideline-supported indication. They do not guarantee healing. Local infection or another specific indication may require a different prescribing decision.
Recognise established disease and differentials
The usual case definition combines relevant medicine exposure, persistent exposed bone or bone probeable through a fistula for more than eight weeks, and exclusion of jaw radiotherapy or metastatic jaw disease. The full definition and clinical context matter. Important disease can also present without obvious exposed bone.
Record pain, infection, fistulae, extent, sensory change and imaging findings. Consider osteomyelitis, traumatic exposure, osteoradionecrosis and malignancy. Suspected disease warrants appropriate specialist assessment; the definition’s time component is not permission to leave concerning symptoms unreviewed for eight weeks.
Avoid an unplanned drug holiday
There is no universal evidence-based holiday that makes dental surgery safe. Altering treatment can compromise cancer or fracture prevention, and denosumab interruption has specific rebound skeletal risks. Medicine decisions require discussion with the prescribing team, informed by the indication and planned treatment.
A dentist should not tell a patient to stop their drug independently. Document the shared plan, timing when relevant and responsibilities for restarting or continuing treatment. A low-risk result from one test or a short period off treatment cannot reliably guarantee freedom from MRONJ.
Manage symptoms, extent and future risk
Specialist treatment may include local hygiene measures, pain relief, treatment of infection when indicated and surgery selected for symptoms, stage, anatomy and patient goals. Conservative care and operative care are options within a considered plan; neither is universally correct for every lesion.
Monitor pain, infection, nutrition, function and progression, and coordinate systemic treatment. Explain that healing and recurrence are uncertain. Record the review route and deterioration advice. The SDCEP 2024 supplement updates incidence information while retaining the core guidance; do not substitute a general population estimate for an individual risk discussion.
A distinction to remember
Never create a drug holiday independently. Avoiding every extraction is not prevention when a persistent infected tooth itself requires treatment.
A patient taking osteoporosis treatment has a painful, non-restorable infected tooth. Must extraction be refused?
Reveal the reasoning
No. Assess the drug and risk category, reasonable alternatives and the harms of retaining infection. Use current SDCEP advice and appropriate consent, technique and review, with referral when needed. Necessary care should be planned proportionately rather than denied because of medicine exposure alone.
Test your recall
Why is the indication for an antiresorptive medicine important?
Show answer
Cancer and osteoporosis regimens differ in dose intensity and clinical context, producing different risk patterns. The medicine name, route, duration and other therapies also matter. Recording only “bisphosphonate use” is insufficient for a useful MRONJ risk assessment and consent discussion.
